Epidemic of influenza A(H1N1)pdm09 analyzed by full genome sequences and the first case of oseltamivir-resistant strain in Myanmar 2017.
Adolescent
Adult
Amino Acid Substitution
Antigens, Viral
Antiviral Agents
/ pharmacology
Child
Child, Preschool
Drug Resistance, Viral
/ genetics
Epidemics
Female
Genome, Viral
Hemagglutinin Glycoproteins, Influenza Virus
/ genetics
Humans
Infant
Influenza A Virus, H1N1 Subtype
/ classification
Influenza, Human
/ drug therapy
Male
Middle Aged
Mutation, Missense
Myanmar
/ epidemiology
Oseltamivir
/ pharmacology
Phylogeny
Young Adult
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2020
2020
Historique:
received:
02
09
2019
accepted:
10
02
2020
entrez:
5
3
2020
pubmed:
5
3
2020
medline:
19
6
2020
Statut:
epublish
Résumé
A community outbreak of human influenza A(H1N1)pdm09 virus strains was observed in Myanmar in 2017. We investigated the circulation patterns, antigenicity, and drug resistance of 2017 influenza A(H1N1)pdm09 viruses from Myanmar and characterized the full genome of influenza virus strains in Myanmar from in-patients and out-patients to assess the pathogenicity of the viruses. Nasopharyngeal swabs were collected from out-patients and in-patients with acute respiratory tract infections in Yangon and Pyinmana City in Myanmar during January-December 2017. A total of 215 out-patients and 18 in-patients infected with A(H1N1)pdm09 were detected by virus isolation and real-time RT-PCR. Among the positive patients, 90.6% were less than 14 years old. Hemagglutination inhibition (HI) antibody titers against A(H1N1)pdm09 viruses in Myanmar were similar to the recommended Japanese influenza vaccine strain for 2017-2018 seasons (A/Singapore/GP1908/2015) and WHO recommended 2017 southern hemisphere vaccine component (A/Michigan/45/2015). Phylogenetic analysis of the hemagglutinin sequence showed that the Myanmar strains belonged to the genetic subclade 6B.1, possessing mutations of S162N and S164T at potential antigenic sites. However, the amino acid mutation at position 222, which may enhance the severity of disease and mortality, was not found. One case with no prior history of oseltamivir treatment possessed H275Y mutated virus in neuraminidase (NA), which confers resistance to oseltamivir and peramivir with elevated IC50 values. The full genome sequence of Myanmar strains showed no difference between samples from in-patients and out-patients, suggesting no additional viral mutations associated with patient severity. Several amino acid changes were observed in PB2, PB1, and M2 of Myanmar strains when compared to the vaccine strain and other Asian strains. However, no mutations associated with pathogenicity were found in the Myanmar strains, suggesting that viral factors cannot explain the underlying reasons of the massive outbreak in Myanmar. This study reported the first detection of an oseltamivir-resistant influenza virus in Myanmar, highlighting the importance of continuous antiviral monitoring and genetic characterization of the influenza virus in Myanmar.
Identifiants
pubmed: 32130243
doi: 10.1371/journal.pone.0229601
pii: PONE-D-19-24652
pmc: PMC7055873
doi:
Substances chimiques
Antigens, Viral
0
Antiviral Agents
0
Hemagglutinin Glycoproteins, Influenza Virus
0
Oseltamivir
20O93L6F9H
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0229601Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Virus Genes. 2019 Aug;55(4):458-464
pubmed: 31129786
Wkly Epidemiol Rec. ;92(11):117-28
pubmed: 28303704
J Clin Microbiol. 2011 Jan;49(1):125-30
pubmed: 21084523
J Virol. 2010 Nov;84(22):12069-74
pubmed: 20826688
Nature. 2004 Dec 16;432(7019):904-6
pubmed: 15602562
Influenza Other Respir Viruses. 2017 Sep;11(5):399-403
pubmed: 28792671
PLoS One. 2016 Dec 20;11(12):e0168464
pubmed: 27997573
PLoS One. 2011 Jan 07;6(1):e16087
pubmed: 21249207
Lancet. 2011 Apr 9;377(9773):1264-75
pubmed: 21435708
Influenza Other Respir Viruses. 2013 Sep;7(5):766-71
pubmed: 23122276
PLoS One. 2017 Apr 14;12(4):e0175655
pubmed: 28410396
BMC Infect Dis. 2018 Dec 7;18(1):637
pubmed: 30526505
PLoS One. 2019 Jan 10;14(1):e0210550
pubmed: 30629691
Int J Mol Sci. 2017 Aug 07;18(8):
pubmed: 28783091
Intervirology. 2009;52(6):310-20
pubmed: 19776616
Wkly Epidemiol Rec. ;91(41):469-84
pubmed: 27758094
Euro Surveill. 2011 Feb 03;16(5):
pubmed: 21315056
Epidemiol Infect. 2017 Oct;145(13):2656-2665
pubmed: 28768557
3 Biotech. 2018 Oct;8(10):408
pubmed: 30237955
J Med Virol. 2018 May;90(5):836-843
pubmed: 29288584
Vaccine X. 2019 Jan 29;1:100011
pubmed: 31384733
PLoS One. 2015 Mar 13;10(3):e0119115
pubmed: 25768797
Am J Pathol. 2015 Jun;185(6):1528-36
pubmed: 25747532
Front Microbiol. 2016 Mar 07;7:262
pubmed: 27014195
BMC Infect Dis. 2014 Sep 04;14:480
pubmed: 25186370
Virusdisease. 2018 Sep;29(3):380-384
pubmed: 30159375
Euro Surveill. 2011 Jun 09;16(23):
pubmed: 21679678
Mol Biol Evol. 2013 Dec;30(12):2725-9
pubmed: 24132122
Euro Surveill. 2010 Mar 04;15(9):
pubmed: 20214869
Antiviral Res. 2017 Oct;146:12-20
pubmed: 28802866
Wkly Epidemiol Rec. 2012 Sep 28;87(39):369-74
pubmed: 23061103